Chapter 13 Targeting the Kinome with Computational Chemistry

Annual Reports in Computational Chemistry

Volumn 1, Issue C, 2005, Pages 185-202

  Lamb, Michelle L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33444462876     PISSN: 15741400     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-1400(05)01013-3     Document Type: Review

References (71)

1. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
2. Hanks S.K., and Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (1995) 576-596
3. Scapin G. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today 7 (2002) 601-611
4. Cherry M., and Williams D.H. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11 (2004) 663-673
5. Noble M.E.M., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
6. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
7. Bridges A.J. Chemical inhibitors of protein kinases. Chem. Rev. 101 (2001) 2541-2571
8. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
9. Metz W.A. A perspective on protein kinase inhibitors. Bioorg. Med. Chem. Lett. 13 (2003) 2953
10. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., and Torcellini C. Pyrazole urea-based inhibitors of p38 map kinase: from lead compound to clinical candidate. J. Med. Chem. 45 (2002) 2994-3008
11. H. Chen, A. Delaney, D. T. Dudley, C. A. Hasemann, Jr., P. Kuffa, P. C. McConnell, J. F. Ohren, A. G. Pavlovsky, H. Tecle, C. E. Whitehead, C. Yan and E. Zhang, Modified MEK1 and MEK2, crystal of a peptide:ligand:cofactor complex containing such modified MEK1 or MEK2, and methods or use thereof, European Patent Application 1321518A1.
12. Hubbard S.R. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. 12 (2002) 735-741
13. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J., and Superti-Furga G. A myristoyl/phosphotyrosine switch regulates C-Abl. Cell 112 (2003) 845-857
14. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., and Kuriyan J. Structural basis for the autoinhibition of C-Abl tyrosine kinase. Cell 112 (2003) 859-871
15. Myshkin E., and Wang B. Chemometrical classification of ephrin ligands and Eph kinases use GRID/CPCA approach. J. Chem. Inf. Comput. Sci. 43 (2003) 1004-1010
16. Sigano D.M., Peach M.L., Nacro K., Choi Y., Lewin N.E., Nicklaus M.C., Blumberg P.M., and Marquez V.E. Differential binding modes of diacylglycerol (DAG) and DAG lactones to protein kinase C (PK-C). J. Med. Chem. 46 (2003) 1571-1579
17. Woolfrey J.R., and Weston G.S. The use of computational methods in the discovery and design of kinase inhibitors. Curr. Pharm. Des. 8 (2002) 1527-1545
18. Mao L., Wang Y., Liu Y., and Hu X. Multiple intermolecular interaction modes of positively charged residues with adenine in ATP-binding proteins. J. Am. Chem. Soc. 125 (2003) 14216-14217
19. Mao L., Wang Y., Liu Y., and Hu X. Molecular determinants for ATP-binding in proteins: a data mining and quantum chemical analysis. J. Mol. Biol. 336 (2004) 787-807
20. Pierce A.C., Sandretto K.L., and Bemis G.W. Kinase inhibitors and the case for CH⋯O hydrogen bonds in protein-ligand binding. Proteins 49 (2002) 567-576
21. Valiev M., Kawai R., Adams J.A., and Weare J.H. The role of the putative catalytic base in the phosphoryl transfer reaction in a protein kinase: first-principles calculations. J. Am. Chem. Soc. 125 (2003) 9926-9927
22. Diaz N., and Field M.J. Insights into the phosphoryl-transfer mechanism of CAMP-dependent protein kinase from quantum chemical calculations and molecular dynamics simulations. J. Am. Chem. Soc. 126 (2004) 529-542
23. Goldsmith-Fischman S., and Honig B. Structural genomics: computational methods for structure analysis. Protein Sci. 12 (2003) 1813-1821
24. Rayan A., Noy E., Chema D., Levitzki A., and Goldblum A. Stochastic algorithm for kinase homology model construction. Curr. Med. Chem. 11 (2004) 674-692
25. Diller D.J., and Li R. Kinases, homology models, and high throughput docking. J. Med. Chem. 46 (2003) 4638-4647
26. Oshiro C., Bradley E.K., Eksterowicz J.E., Evensen E., Lamb M.L., Lanctot J.K., Putta S., Stanton R., and Grootenhuis P.D.J. Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 47 (2004) 764-767
27. Muegge I., and Enyedy I.J. Virtual screening for kinase targets. Curr. Med. Chem. 11 (2004) 693-707
28. Hindle S.A., Rarey M., Buning C., and Lengauer T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 16 (2002) 129-149
29. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., and Shenkin P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004) 1739-1749
30. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., and Banks J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47 (2004) 1750-1759
31. Ewing T.J.A., and Kuntz I.D. Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 18 (1997) 1175-1189
32. Jones G., Willett P., Glen R.C., Leach A.R.L., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
33. Buzko O.V., Bishop A.C., and Shokat K.M. Modified autodock for accurate docking of protein kinase inhibitors. J. Comput.-Aided Mol. Des. 16 (2002) 113-127
34. Cavasotto C.N., and Abagyan R.A. Protein flexibility in ligand docking and virtual screening to protein kinases. J. Mol. Biol. 337 (2004) 209-225
35. Assefa H., Kamath S., and Buolamwini J.K. 3-D QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J. Comput.-Aided Mol. Des. 17 (2003) 475-493
36. Kr ̌i{dotless} ́z ̌ Z., Otyepka M., Ba ́rtova ́ I., and Koc ̌a J. Analysis of CDK2 active-site hydration: a method to design new inhibitors. Proteins 55 (2004) 258-274
37. Tominaga Y., and Jorgensen W.L. General model for estimation of the inhibition of protein kinases using Monte Carlo simulations. J. Med. Chem. 47 (2004) 2534-2549
38. Mallanack D.T., Pitt W.R., Gancia E., Montana J.G., Livingstone D.J., Ford M.G., and Whitley D.C. Selecting screening candidates for kinase and G protein-coupled receptor targets using neural networks. J. Chem. Inf. Comput. Sci. 42 (2002) 1256-1262
39. Kissau L., Stahl P., Mazitschek R., Giannis A., and Waldmann H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J. Med. Chem. 46 (2003) 2917-2931
40. Rockey W.M., and Elcock A.H. Progress toward virtual screening for drug side effects. Proteins 48 (2002) 664-671
41. Tøndel K., Anderssen E., and Drabløs F. Protein alpha shape similarity analysis (PASSA): a new method for mapping protein binding sites. Application in the design of a selective inhibitor of tyrosine kinase 2. J. Comput.-Aided Mol. Des. 16 (2002) 831-840
42. Naumann T., and Matter H. Structural classification of protein kinases using 3d molecular interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 45 (2002) 2366-2378
43. Böhmer F.D., Karagyozov L., Uecker A., Serve H., Botzki A., Mahboobi S., and Dove S. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278 (2003) 5148-5155
44. Anderson M., Beattie J.F., Breault G.A., Breed J., Byth K.F., Culshaw J.D., Ellston R.P.A., Green S., Minshull C.A., Norman R.A., Pauptit R.A., Stanway J., Thomas A.P., and Jewsbury P.J. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg. Med. Chem. Lett. 13 (2003) 3021-3026
45. Pierce A.C., Rao G., and Bemis G.W. BREED: generating novel inhibitors through hybridization of known ligands. J. Med. Chem. 47 (2004) 2768-2775
46. Wu S.Y., McNae I., Kontopidis G., McClue S.J., McInnes C., Stewart K.J., Wang S., Zheleva D.I., Marriage H., Lane D.P., Taylor P., Fischer P.M., and Walkinshaw M.D. Discovery of a novel family of CDK inhibitors with the program LIDEAUS: structural basis for ligand-induced disordering of the activation loop. Structure 11 (2003) 399-410
47. Bradley E.K., Miller J.L., Saiah E., and Grootenhuis P.D.J. Informative library design as an efficient strategy to identify and optimize leads: application to cyclin-dependent kinase 2 antagonists. J. Med. Chem. 46 (2003) 4360-4364
48. Eksterowicz J.E., Evensen E., Lemmen C., Brady G.P., Lanctot J.K., Bradley E.K., Saiah E., Robinson L.A., Grootenhuis P.D.J., and Blaney J.M. Coupling structure-based design with combinatorial chemistry: application of active site derived pharmacophores with informative library design. J. Mol. Graph. Model. 20 (2002) 469-477
49. Hecker E.A., Duraiswami C., Andrea T.A., and Diller D.J. Use of catalyst pharmacophore models for screening of large combinatorial libraries. J. Chem. Inf. Comput. Sci. 42 (2002) 1204-1211
50. Catalyst, Accelrys, Inc., San Diego, CA.
51. Sims P.A., Wong C.F., and McCammon J.A. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors. J. Med. Chem. 46 (2003) 3314-3325
52. Kunick C., Lauenroth K., Wieking K., Xie X., Schultz C., Gussio R., Zaharevitz D., Leost M., Meijer L., Weber A., Jørgensen F.S., and Lemcke T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J. Med. Chem. 47 (2004) 22-36
53. Polychronopoulos P., Magiatis P., Skaltsounis A.-L., Myrianthopoulos V., Mikros E., Tarricone A., Musacchio A., Roe S.M., Pearl L., Leost M., Greengard P., and Meijer L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 47 (2004) 935-946
54. Hamdouchi C., Keyser H., Collins E., Jaramillo C., de Diego J.E., Spencer C.D., Dempsey J.A., Anderson B.D., Leggett T., Stamm N.B., Schultz R.M., Watkins S.A., Cocke K., Lemke S., Burke T.F., Beckmann R.P., Dixon J.T., Gurganus T.M., Rankl N.B., Houck K.A., Zhang F., Vieth M., Espinosa J., Timm D.E., Campbell R.M., Patel B.K.R., and Brooks H.B. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol. Cancer Ther. 3 (2004) 1-9
55. Mavunkel B.J., Chakravarty S., Perumattam J.J., Luedtke G.R., Liang X., Lim D., Xu Y.-., Laney M., Liu D.Y., Schreiner G.F., Lewicki J.A., and Dugar S. Indole-based heterocyclic inhibitors of p38α MAP kinase: designing a conformationally restricted analogue. Bioorg. Med. Chem. Lett. 13 (2003) 3087-3090
56. Ottosen E.R., Sørensen M.D., Björkling F., Skak-Nielsen T., Fjording M.S., Aaes H., and Binderup L. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 map kinase inhibitors with high antiinflammatory activity. J. Med. Chem. 46 (2003) 5651-5662
57. Kamath S., and Buolamwini J.K. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J. Med. Chem. 46 (2003) 4657-4668
58. Peng T., Pei J., and Zhou J. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM). J. Chem. Inf. Comput. Sci. 43 (2003) 298-303
59. Underiner T.L., Ruggeri B., and Gingrich D.E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 11 (2004) 731-745
60. Fraley M.E., Hoffman W.F., Arrington K.L., Hungate R.W., Hartman G.D., McFall R.C., Coll K.E., Rickert K., Thomas K.A., and McGaughey G.B. Property-based design of KDR kinase inhibitors. Curr. Med. Chem. 11 (2004) 709-719
61. Moffat D.F.C., Allen R.A., Rapecki S.E., Davis P.D., O'Connell J., Hutchings M.C., King M.A., Boyce B.A., and Perry M.J. 4-Thiophenoxy-N-(3,4,5-trialkoxyphenyl)pyrimidine-2-amines as potent and selective inhibitors of the T-cell tyrosine kinase p56lck. Curr. Med. Chem. 11 (2004) 747-753
62. Sundaramoorthi R., Shakespeare W.C., Keenan T.P., Metcalf III C.A., Wang Y., Mani U., Taylor M., Liu S., Bohacek R.S., Narula S.S., Dalgarno D.C., van Schravendijk M.R., Violette S.M., Liou S., Adams S., Ram M.K., Keats J.A., Weigele M., and Sawyer T.K. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Bioorg. Med. Chem. Lett. 13 (2003) 3063-3066
63. Furet P., Bold G., Hofmann F., Manley P., Meyer T., and Altmann K.-H. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorg. Med. Chem. Lett. 13 (2003) 2967-2971
64. Lyne P.D., Kenny P.W., Cosgrove D.A., Deng C., Zabludoff S., Wendoloski J.J., and Ashwell S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 47 (2004) 1962-1968
65. Takami A., Iwakubo M., Okada Y., Kawata T., Odai H., Takahashi N., Shindo K., Kimura K., Tagami Y., and Miyake M. Design and synthesis of Rho kinase inhibitors (I). Bioorg. Med. Chem. 12 (2004) 2115-2137
66. Vankayalapati H., Bearss D.J., Saldanha J.W., Muñoz R.M., Rojanala S., von Hoff D.D., and Mahadevan D. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol. Cancer Ther. 2 (2003) 283-294
67. Singh J., Chuaqui C.E., Boriack-Sjodin P.A., Lee W.-C., Pontz T., Corbley M.J., Cheung H.-K., Arduini R.M., Mead J.N., Newman M.N., Papadatos J.L., Bowes S., Josiah S., and Ling L.E. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg. Med. Chem. Lett. 13 (2003) 4355-4359
68. Vangrevelinghe E., Zimmermann K., Schoepfer J., Portmann R., Fabbro D., and Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46 (2003) 2656-2662
69. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
70. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
71. Paez J.G., Ja ̈nne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500